Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
Kai Rejeski, Specialist in Internal Medicine and Hematology and Oncology at LMU Klinikum München, shared a post on X about a recent article he and his colleagues co-authored, adding:
”Not all CHIP is created equal when it comes to CAR-T…TP53 mutant CHIP stands out:
- more cytopenias, higher baseline CAR hematotox, reduced CAR expansion and inferior outcomes
- distinct inflamm. proteomic signature”
Title: TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy
Authors: Giulia Rappa, Frank Ziemann, Kieron White, Linus Kruk, Samar Shamas, Amelie Muth, Kayleen Shi, Cristina Zucchinetti, Savanna Süß, Maja Rothenberg-Thurley, Alessandra Holzem, Tobias Tix, Agnese Petrera, Bianka Ksienzyk, Charlotte Bentenrieder, Katharina S. Götze, Fabian Müller, Veit Bücklein, Kai Rejeski, Marion Subklewe
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 26, 2026, 18:27Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero
-
Aug 26, 2026, 18:24New Educational Content for the Bleeding Disorders Community – EAHAD
-
Aug 26, 2026, 18:14N. Mariana S. Vasquez: From Skin and Gut to Celiac Disease
-
Aug 26, 2026, 18:13Francesca Granata: What Happens When Patients Become Researchers and Researchers Become Advocates?
-
Aug 26, 2026, 18:11Maxima Mendez: Statins Are No Longer the Whole Story
-
Aug 26, 2026, 18:06Ashkan Shoamanesh: ANNEXa-I Analyses Inform Individualized Treatment in Intracranial Hemorrhage
-
Aug 26, 2026, 18:01Sam Tsimikas: Lp(a) and Oxidized Phospholipids Reveal a New Link Between Hypercoagulability and Stronger Clot Formation
-
Aug 26, 2026, 17:52Kamlesh Darji: A Practical Guide to Interpreting Coagulation Tests
-
Aug 26, 2026, 17:46Bruno Pougault: The Hidden Burden of Hemostatic Disorders in Women